What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock is trading lower on Thursday; however, there is no news to justify the movement. The stock could possibly be down on profit-taking after the stock closed nearly 15% higher on Wednesday.
On Tuesday, the company shared positive results from its Phase 1b clinical trial for its lead candidate, PH-762.
PH-762 Shows 85% Pathological Response Rate
Phio Pharmaceuticals’ lead clinical program is PH-762 (often referred to in the context of their INTASYL platform), which is an investigational, self-delivering RNAi compound designed to treat skin cancers. It works by silencing the PD-1 gene to enhance the immune system’s ability to kill tumor cells.
Phio Pharmaceuticals recently announced positive results from its Phase 1b clinical trial for its lead candidate, PH-762, which showed an 85% pathological response rate at the highest dose concentration.
The trial involved 22 patients with cutaneous carcinomas, and the Safety Monitoring Committee reported no serious adverse events, indicating a promising outlook for the drug.
The company is targeting an FDA submission for guidance on clinical study design for PH-762 in the second quarter of 2026, with plans to commence manufacturing of cGMP material by the second half of 2026. These developments highlight the potential of PH-762 as a non-surgical treatment for skin cancers.
PHIO Mixed Technical Indicators
The stock is currently trading 18.4% above its 20-day simple moving average (SMA) but is 18.3% below its 100-day SMA, indicating mixed signals in the short to medium term. Over the past 12 months, shares have decreased by approximately 29.51% and are currently positioned closer to their 52-week lows than highs.
The RSI is at 66.61, which is considered neutral territory, while the MACD is above its signal line, indicating bullish momentum. The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock.
- Key Resistance: $1.50
- Key Support: N/A
Analyst Consensus & Recent Actions:
The stock carries a Buy Rating with an average price target of $10.67. Recent analyst moves include:
- HC Wainwright & Co.: Buy (Maintains Target to $14.00) (Feb. 10)
PHIO Price Action: Phio Pharma shares were down 4.65% at $1.23 during premarket trading on Thursday.
Photo by Aunt Spray via Shutterstock
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Microsoft (MSFT.US) offers voluntary buyout packages to about 60,000 employees: Structural divergence in U.S. employment under AI transformation
In 2026, the U.S. labor market is characterized by both low layoffs and weak hiring. Companies like Microsoft and American Express are leveraging AI to optimize their workforce, while data centers are driving growth in the construction sector. However, entry-level white-collar jobs face increasing pressure, with real wages experiencing negative growth and structural transformation risks becoming more prominent.
"Inflation is really too high"! Federal Reserve "third-in-command": The Fed must continue to take action and promptly bring the price level back to 2%
John Williams, President of the New York Federal Reserve and the “number three” official at the Federal Reserve with a permanent voting right, stated that U.S. inflation remains high and policymakers must take further action to curb price pressures.
Jensen Huang steps down, and the "biggest patron" of new AI players is gone too
Anthropic's tens-of-billions IPO investment, Figure AI's additional $1 billion, and Nscale's over $5 billion credit guarantee are all in negotiations but their outcomes remain uncertain. Meanwhile, its $500 billion AI financing platform has stalled, and some clients are considering switching to AMD or Google. Successor Kress has a conservative style and has repeatedly vetoed deals aggressively promoted by Jensen Huang, signaling the possible end of Nvidia's era of bold investments.
Crypto prices
More
